The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US
Open Access
- 13 July 2021
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 5 (4) , 727-736
Abstract
Background Overactive bladder (OAB) is a prevalent condition commonly treated with anticholinergic medications. The extent to which anticholinergic burden is associated with costs and healthcare resource use (HCRU) in the long-stay nursing home (LSNH) setting is currently unknown. Objectives This research evaluated the impact of anticholinergic burden on HCRU and related costs among LSNH residents with OAB. Methods This was a cohort study based on 2013–2015 Minimum Data Set-linked Medicare claims data involving LSNH residents aged ≥ 65 years with OAB and having Parts A, B and D coverage 6 months pre- and ≥ 12 months post-nursing home admission date (index date). Cumulative anticholinergic burden was determined using the Anticholinergic Cognitive Burden scale and defined daily dose. Direct medical costs related to HCRU were examined. HCRU included inpatient, outpatient, emergency room (ER), and physician office visits. Costs and HCRU associated with levels of anticholinergic burden were evaluated using generalized linear models. Results A total of 123,308 LSNH residents with OAB were included in this study. Most residents (87.2%) had some level (12.8%, none; 18.0%, low; 41.9%, moderate; and 27.3%, high) of cumulative anticholinergic burden. Results indicate that all types of resource utilization were higher among those with any level of anticholinergic burden than those with no burden. The outpatient, ER, and physician costs tended to be higher with increasing anticholinergic burden. Conclusions Costs and HCRU patterns reflected increasing trends with anticholinergic burden. Targeted efforts towards reducing anticholinergic burden among LSNH residents with OAB may result in decreases in costs and HCRU.Keywords
Funding Information
- Astellas Pharma Global Development
This publication has 35 references indexed in Scilit:
- Algorithm for Identifying Nursing Home Days Using Medicare Claims and Minimum Data Set Assessment DataMedical Care, 2016
- Impact of High Risk Drug Use on Hospitalization and Mortality in Older People with and without Alzheimer’s Disease: A National Population Cohort StudyPLOS ONE, 2014
- Reducing Cost by Reducing Polypharmacy: The Polypharmacy Outcomes ProjectJournal of the American Medical Directors Association, 2012
- Prevalence and Effect on Health‐Related Quality of Life of Overactive Bladder in Older Americans: Results from the Epidemiology of Lower Urinary Tract Symptoms StudyJournal of the American Geriatrics Society, 2011
- Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing StudyJournal of the American Geriatrics Society, 2011
- Prevalence and Predictors of Anticholinergic Medication Use in Elderly Nursing Home Residents with DementiaDrugs & Aging, 2010
- Economic Costs of Overactive Bladder in the United StatesUrology, 2010
- The Multiple Propensity Score as Control for Bias in the Comparison of More Than Two Treatment ArmsMedical Care, 2010
- Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder DysfunctionAdvances in Urology, 2009
- Impact of Anticholinergics on the Aging Brain: A Review and Practical ApplicationAging Health, 2008